Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Uso de boro y sus derivados para el tratamiento de distrofias musculares

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20190226002
Publicado:
07/03/2019
Caducidad:
07/03/2020
Resumen:
Un centro de investigación español que reúne algunos de los principales grupos de investigación españoles en biomedicina de más de 100 instituciones (universidades, hospitales y centros tecnológicos) ha desarrollado un nuevo tratamiento de distrofias musculares basado en la administración de boro o un compuesto de boro. La nueva tecnología introduce una nueva estrategia para controlar microentornos celulares a nivel molecular en el tratamiento de distrofias musculares. El boro y sus derivados pueden utilizarse como sistemas terapéuticos de distrofias musculares para las que actualmente no ha tenido éxito ningún tratamiento, como es el caso de la distrofia muscular de Duchenne (DMD) y la distrofia miotónica (DM). El centro de investigación busca socios industriales y académicos con el fin de establecer acuerdos de licencia, investigación o cooperación técnica.

Details

Tittle:
Use of boron and its derivatives for the treatment of muscular dystrophies
Summary:
A Spanish research centre has developed a new treatment for muscular dystrophies based on the administration of boron or a compound of boron, They seek license, research cooperation or technical cooperation agreements with both the industry and academia.
Description:
This research networking center gathers some of the main Spanish research groups in biomedicine, located in more than 100 institutions as universities, hospitals and technological centers distributed around the country.
The new technology introduces an innovative strategy to control cell microenvironments at molecular level for the treatment of muscular dystrophies.
Boron is an essential metalloid, which plays a key role in plants and animal metabolisms. It has been reported that boron is involved in bone mineralization, has some uses in synthetic chemistry and its potential has been only recently exploited in medicinal chemistry. Little is known about boron homeostasis and function in animal cells. It has been reported that boron is involved in mouse myogenic differentiation.
Boron and its derivatives can be used as therapeutic systems for muscular dystrophies for which currently no successful treatment has been obtained, for example, Duchenne muscular dystrophy (DMD) and myotonic dystrophy (DM).
DMD is a progressive and lethal disease, caused by X-linked mutations of the dystrophin encoding gene. The lack of dystrophin leads to weakness, degeneration, and consequent fibrosis in skeletal and cardiac muscles. Nowadays, there is no cure for DMD patients.
They are looking to establish license, research cooperation or technical cooperation agreements.
Advantages and Innovations:
DM is a dominantly inherited neuromuscular disorder (rare disease) for which currently there is no cure or effective treatment. Several therapeutic approaches have been tested, although with no clear success.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
Patent ready for licensing-out via license agreements.

They are seeking industrial partners, either Biotech or Pharma, to:
- enter into preclinical R-Y-D collaboration (in vitro and/or in vivo drug testing)
- Further development until clinical proof-of-concept

Besides, the research center is looking for R-Y-D institutions to establish technical cooperation agreements or research cooperation agreements.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001015 Productos farmacéuticos / medicamentos